A 66-year-old man presents 2 months after a non-cardioembolic ischaemic stroke with residual left arm weakness. He is on aspirin 81 mg daily and high-intensity statin therapy. He has no atrial fibrillation. According to Canadian secondary stroke prevention guidance, which antithrombotic strategy is most appropriate long term?